The Diagnostic Value of Modified Systemic ınflammation Score in Predicting Post-operative Outcomes of Cutaneous Melanoma Patients Who Underwent ısolated Limb Perfusion

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2021 Nov 16

PMID 34781987

Citations 1

Authors

Sevket Baris Morkavuk

Serdar Culcu

Ebru Esen

Ali Ekrem Unal

Affiliations

Soon will be listed here.

Abstract

Background: In-transit metastasis is considered a locoregional disease in cutaneous melanoma (CM) patients. Isolated limb perfusion (ILP) is among the treatment options in selected cases. The aim of this study was to determine the success of pre- and post-perfusion mSIS values in predicting the potential complications and the prognosis of the disease by investigating the early and long-term results of mSIS values calculated before and after ILP in CM cases with in-transit metastases.

Materials And Methods: Patients who underwent ILP within the period from 2014 to 2020 in our department were retrospectively scanned. A total of 20 patients were found to undergo ILP. The scores obtained from modified inflammation score (mSIS) were formulated according to albumin (Alb) and lymphocyte to monocyte ratio (LMR) scores.

Results: The mean follow-up time was 20.47 months. Complications requiring surgical intervention developed in three patients. According to the Wieberdink local toxicity classification, the majority (70%) of the patients were found to be grade II. Based on pre-perfusion mSIS values, 8 patients were classified as mSIS 0 while six patients were classified as mSIS 1 and 2. Based on post-perfusion mSIS values, 14 patients and one patient were classified as mSIS 2 (70%) and mSIS 0, respectively. Accordingly, univariate analysis showed that mSIS 1 and mSIS 2 were negative prognostic factors for mean survival in the pre-perfusion period (HR 0.162, 95% CI 0.036-0.729; p = 0.018 and HR: 0.223, 95% CI 0.049-1.019; p = 0.053) whereas albumin (Alb) and lymphocyte to monocyte ratio (LMR) were not independent prognostic factors for mean survival.

Conclusion: The mSIS values calculated in the pre-perfusion period can give an opinion about the OS of the patients whereas post-perfusion mSIS values may predict potential surgical complications and local toxicities.

Citing Articles

Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review.

Gradel K J Clin Med. 2023; 12(19).

PMID: 37834777 PMC: 10573484. DOI: 10.3390/jcm12196132.

References

Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kondo T . Comparison of Preoperative Inflammation-based Prognostic Scores in Patients With Colorectal Cancer. Ann Surg. 2016; 267(3):527-531. DOI: 10.1097/SLA.0000000000002115. View

Viale P . The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2021; 11(2):135-136. PMC: 7848816. DOI: 10.6004/jadpro.2020.11.2.1. View

Huang H, Chen L, Fang X, Guo C, Lin X, Hong H . Prognostic Value of the Modified Systemic Inﬂammation Score in Patients With Extranodal Natural Killer/T-Cell Lymphoma. Front Pharmacol. 2020; 11:593392. PMC: 7554510. DOI: 10.3389/fphar.2020.593392. View

Kim E, Lee J, Yoo H, Park C, Song K . The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer?. Ann Surg Oncol. 2015; 22(13):4363-70. DOI: 10.1245/s10434-015-4518-z. View

Ekwueme D, Guy Jr G, Li C, Rim S, Parelkar P, Chen S . The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol. 2011; 65(5 Suppl 1):S133-43. DOI: 10.1016/j.jaad.2011.04.036. View

Williams P, Olsen C, Hayward N, Whiteman D . Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer. 2010; 129(7):1730-40. DOI: 10.1002/ijc.25804. View

Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G . Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002; 147(1):62-70. DOI: 10.1046/j.1365-2133.2002.04867.x. View

Arroyo V, Garcia-Martinez R, Salvatella X . Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014; 61(2):396-407. DOI: 10.1016/j.jhep.2014.04.012. View

Lin J, Lin J, Xie J, Wang J, Lu J, Chen Q . Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer. Gastric Cancer. 2018; 22(2):403-412. DOI: 10.1007/s10120-018-0854-6. View

10.

Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T . Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Ann Surg. 2020; 272(2):342-351. DOI: 10.1097/SLA.0000000000003239. View

11.

Thompson J, Lai D, Ingvar C, Kam P . Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994; 4 Suppl 1:45-50. View

12.

Francken A, Accortt N, Shaw H, Wiener M, Soong S, Hoekstra H . Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008; 15(5):1476-84. DOI: 10.1245/s10434-007-9717-9. View

13.

Clavien P, Sanabria J, Strasberg S . Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992; 111(5):518-26. View

14.

Mian R, Henderson M, Speakman D, Finkelde D, Ainslie J, Mckenzie A . Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. 2001; 44(3):189-92. PMC: 3699125. View

15.

WIEBERDINK J, Benckhuysen C, Braat R, VAN SLOOTEN E, Olthuis G . Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982; 18(10):905-10. DOI: 10.1016/0277-5379(82)90235-8. View

16.

Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A . Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010; 15(4):416-27. PMC: 3227960. DOI: 10.1634/theoncologist.2009-0325. View

17.

Jemal A, Saraiya M, Patel P, Cherala S, Barnholtz-Sloan J, Kim J . Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011; 65(5 Suppl 1):S17-25.e1-3. DOI: 10.1016/j.jaad.2011.04.032. View

18.

Dunn G, Old L, Schreiber R . The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2):137-48. DOI: 10.1016/j.immuni.2004.07.017. View

19.

Tronnier M, Semkova K, Wollina U, Tchernev G . Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach. Wien Med Wochenschr. 2013; 163(15-16):354-8. DOI: 10.1007/s10354-013-0207-3. View

20.

Pollard J . Trophic macrophages in development and disease. Nat Rev Immunol. 2009; 9(4):259-70. PMC: 3648866. DOI: 10.1038/nri2528. View